Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information

Core Viewpoint - A class action lawsuit has been initiated against Revance Therapeutics, Inc. to recover losses for investors who acquired securities between February 29, 2024, and December 6, 2024 [1][2] Summary by Sections Lawsuit Details - The lawsuit alleges that Revance made false statements and concealed material breaches of a Distribution Agreement with Teoxane, which granted Revance exclusive rights to market and distribute Teoxane's dermal fillers [2] - The complaint claims that these actions increased the risk of litigation and monetary and reputational harm to the company [2] - It is also alleged that these issues raised the likelihood of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2] Investor Actions - Investors who incurred losses during the specified class period have until March 4, 2025, to apply to become the lead plaintiff in the lawsuit [3] - The lead plaintiff will represent all class members and can choose a law firm to litigate the case [3] - Participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery from the lawsuit [3] Law Firm Information - Johnson Fistel, LLP is a recognized law firm specializing in shareholder rights and securities class action lawsuits, with offices in multiple states [4] - The firm represents both individual and institutional investors, including foreign investors who have purchased on US exchanges [4]